

# Interactions with HCC Therapies

Charts revised March 2025. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

Page 1 of 6

**Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.**

Atezo + Bez, Atezolizumab + bevacizumab; LEN, lenvatinib; PEM, pembrolizumab; REG, regorafenib; SOR, sorafenib.

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Anaesthetics and Muscle Relaxants</b>					
Bupivacaine	◆	◆	◆	▲	▲
Cisatracurium	◆	◆	◆	◆	◆
Desflurane	◆	◆	◆	◆	◆
Dexmedetomidine	◆	■	◆	◆	■
Ephedrine	◆	▲	◆	▲	◆
Etidocaine	◆	◆	◆	◆	◆
Halothane	◆	◆	◆	◆	◆
Isoflurane	◆	■	◆	◆	■
Ketamine	◆	◆	◆	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆
Propofol	◆	■	◆	■	■
Remifentanyl	◆	◆	◆	◆	◆
Rocuronium	◆	◆	◆	◆	▲
Sevoflurane	◆	■	◆	◆	■
Tetracaine	◆	◆	◆	◆	◆
Thiopental	◆	◆	◆	◆	◆
Tizanidine	◆	▲	◆	◆	▲
<b>Analgesics</b>					
Acetofenac	◆	◆	◆	◆	◆
Alfentanil	◆	◆	◆	◆	◆
Aspirin	◆	◆	◆	◆	◆
Buprenorphine	◆	◆	◆	◆	◆
Celecoxib	◆	◆	◆	◆	◆
Codeine	◆	◆	◆	◆	◆
Dexketoprofen	◆	◆	◆	◆	◆
Dextropropoxyphene	◆	◆	◆	◆	◆
Diamorphine	◆	◆	◆	◆	◆
Diclofenac	◆	◆	◆	◆	◆
Diffunisal	◆	◆	◆	●	◆
Dihydrocodeine	◆	◆	◆	▲	▲
Etoricoxib	◆	◆	◆	◆	◆
Fentanyl (Prescribed)	◆	◆	◆	◆	◆
Flurbiprofen	◆	◆	◆	◆	◆
Hydrocodone	◆	◆	◆	◆	◆
Hydromorphone	◆	◆	◆	◆	◆
Ibuprofen	◆	◆	◆	◆	◆
Indometacin	◆	◆	◆	◆	◆
Ketoprofen	◆	◆	◆	◆	◆
Mefenamic acid	◆	◆	◆	●	◆
Meloxicam	◆	◆	◆	◆	◆
Metamizole (Dipyrone)	◆	◆	●	■	■
Methadone	◆	■	◆	◆	■
Morphine	◆	◆	◆	◆	◆
Naproxen	◆	◆	◆	◆	◆
Nefopam	◆	◆	◆	◆	◆
Oxycodone	◆	◆	◆	◆	◆
Paracetamol (Acetaminophen)	◆	◆	◆	▲	■
Pethidine (Meperidine)	◆	◆	◆	◆	◆
Piroxicam	◆	◆	◆	◆	◆
Tapentadol	◆	◆	◆	◆	◆
Tramadol	◆	▲	◆	◆	▲

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Anthelmintics</b>					
Albendazole	◆	◆	◆	◆	◆
Ivermectin	◆	◆	◆	◆	◆
Nicosamide	◆	◆	◆	◆	◆
Oxamniquine	◆	◆	◆	◆	◆
Praziquantel	◆	◆	◆	◆	◆
Pyrantel	◆	◆	◆	◆	◆
<b>Antiarrhythmics</b>					
Amiodarone	◆	■	◆	▲	■
Bepridil	◆	■	◆	◆	■
Digoxin	◆	◆	◆	◆	■
Disopyramide	◆	■	◆	◆	■
Dofetilide	◆	■	◆	◆	■
Dronedarone	◆	■	◆	●	■
Flecainide	◆	■	◆	◆	■
Lidocaine (Lignocaine)	◆	◆	◆	◆	◆
Mexiletine	◆	◆	◆	◆	◆
Propafenone	◆	●	◆	◆	●
Quinidine	◆	■	◆	▲	■
Vernakalant	◆	■	◆	◆	■
<b>Antibacterials</b>					
Amikacin	◆	◆	◆	◆	◆
Amoxicillin	◆	◆	◆	◆	◆
Ampicillin	◆	◆	◆	◆	◆
Azithromycin	◆	■	◆	◆	■
Aztreonam	◆	◆	◆	◆	◆
Bedaquiline	◆	■	◆	◆	■
Benzylicillin	◆	◆	◆	◆	◆
Bezlotoxumab	◆	◆	◆	◆	◆
Capreomycin	◆	◆	◆	◆	◆
Cefaclor	◆	◆	◆	◆	◆
Cefadroxil	◆	◆	◆	◆	◆
Cefalexin	◆	◆	◆	◆	◆
Cefazolin	◆	◆	◆	◆	◆
Cefixime	◆	◆	◆	◆	◆
Cefotaxime	◆	◆	◆	◆	◆
Cefradine	◆	◆	◆	◆	◆
Ceftaroline	◆	◆	◆	◆	◆
Ceftazidime	◆	◆	◆	◆	◆
Ceftriaxone	◆	◆	◆	◆	◆
Cefuroxime	◆	◆	◆	◆	◆
Chloramphenicol	◆	◆	◆	■	▲
Ciprofloxacin	◆	■	◆	●	■
Clarithromycin	◆	■	◆	●	■
Clavulanic acid	◆	◆	◆	▲	◆
Clindamycin	◆	◆	◆	▲	◆

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HCC Therapies

Charts revised March 2025. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

Page 2 of 6

**Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.**

Atezo + Bez, Atezolizumab + bevacizumab; LEN, lenvatinib; PEM, pembrolizumab; REG, regorafenib; SOR, sorafenib.

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Antibacterials continued</b>					
Clofazimine	◆	◆	◆	●	◆
Cloxacillin	◆	◆	◆	◆	◆
Cycloserine	◆	◆	◆	◆	◆
Dapsone	◆	◆	◆	◆	◆
Daptomycin	◆	◆	◆	◆	◆
Delamanid	◆	■	◆	◆	■
Ertapenem	◆	◆	◆	◆	◆
Erythromycin	◆	■	◆	●	■
Ethambutol	◆	◆	◆	◆	◆
Flucloxacillin	◆	◆	◆	▲	▲
Fosfomycin	◆	◆	◆	◆	◆
Gentamicin	◆	◆	◆	◆	◆
Imipenem	◆	◆	◆	◆	◆
Isoniazid	◆	◆	◆	◆	◆
Levofloxacin	◆	■	◆	◆	■
Linezolid	◆	◆	◆	▲	◆
Lymecycline	◆	◆	◆	◆	◆
Meropenem	◆	◆	◆	◆	◆
Methenamine	◆	◆	◆	◆	◆
Metronidazole	◆	◆	◆	▲	◆
Moxifloxacin	◆	●	◆	■	●
Nitrofurantoin	◆	◆	◆	◆	◆
Norfloxacin	◆	◆	◆	◆	◆
Ofoxacin	◆	■	◆	◆	■
Penicillin V	◆	◆	◆	◆	◆
Piperacillin	◆	◆	◆	◆	◆
Pivmecillinam	◆	◆	◆	◆	◆
Pretomanid	▲	■	▲	▲	■
Pyrazinamide	◆	◆	◆	◆	◆
Rifabutin	◆	◆	◆	●	●
Rifampicin	◆	◆	◆	●	●
Rifapentine	◆	◆	◆	●	●
Rifaximin	◆	◆	◆	▲	▲
Spectinomycin	◆	◆	◆	◆	◆
Streptomycin	◆	◆	◆	◆	◆
Sulfadiazine	◆	◆	◆	◆	◆
Tazobactam	◆	◆	◆	◆	◆
Telithromycin	◆	■	◆	●	■
Temocillin	◆	◆	◆	◆	◆
Tetracyclines	◆	◆	◆	◆	◆
Ticarcillin	◆	◆	◆	◆	◆
Trimethoprim/Sulfamethoxazole	◆	◆	◆	◆	◆
Troleandomycin	◆	◆	◆	●	◆
Vancomycin	◆	◆	◆	◆	◆
<b>Anticoagulant, Anti-platelet and Fibrinolytic</b>					
Abciximab	▲	▲	◆	▲	▲
Acenocoumarol	■	◆	◆	■	■
Anagrelide	◆	◆	◆	■	◆
Apixaban	■	◆	◆	■	▲
Caplacizumab	◆	◆	◆	◆	◆
Clopidogrel	◆	◆	◆	◆	◆
Dabigatran	■	◆	◆	■	▲
Dalteparin	■	◆	◆	■	◆
Danaparoid	■	◆	◆	■	◆
Dipyridamole	◆	◆	◆	■	▲
Edoxaban	■	◆	◆	■	▲
Enoxaparin	■	◆	◆	■	◆
Fluindione	■	◆	◆	■	■
Fondaparinux	■	◆	◆	■	◆
Heparin	■	◆	◆	■	◆
Natalizumab	▲	▲	◆	▲	◆
Phenprocoumon	■	◆	◆	■	■
Prasugrel	■	◆	◆	■	◆
Rivaroxaban	■	◆	◆	■	▲
Streptokinase	◆	◆	◆	■	◆
Ticagrelor	◆	◆	◆	■	▲
Ticlopidine	◆	◆	◆	■	◆
Tinzaparin	■	◆	◆	■	◆
Warfarin	■	◆	◆	■	■

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Anticonvulsants</b>					
Carbamazepine	◆	◆	◆	●	●
Clonazepam	◆	◆	◆	◆	◆
Eslicarbazepine	◆	◆	◆	●	●
Ethosuximide	◆	◆	◆	◆	◆
Gabapentin	◆	◆	◆	◆	◆
Lacosamide	◆	◆	◆	◆	◆
Lamotrigine	◆	◆	◆	◆	◆
Levetiracetam	◆	◆	◆	◆	◆
Oxcarbazepine	◆	◆	◆	●	●
Ethosuximide	◆	◆	◆	◆	◆
Perampanel	◆	◆	◆	◆	◆
Phenobarbital	◆	◆	◆	●	●
Phenytoin	◆	◆	◆	●	●
Pregabalin	◆	◆	◆	◆	◆
Primidone	◆	◆	◆	●	●
Retigabine	◆	◆	◆	◆	◆
Rufinamide	◆	◆	◆	◆	◆
Sultiame	◆	◆	◆	◆	◆
Tiagabine	◆	◆	◆	◆	◆
Topiramate	◆	◆	◆	◆	◆
Valproic acid (Divalproex)	◆	◆	◆	■	▲
Vigabatrin	◆	◆	◆	◆	◆
Zonisamide	◆	◆	◆	◆	◆
<b>Antidepressants</b>					
Agomelatine	◆	◆	◆	◆	◆
Amitriptyline	◆	■	◆	◆	■
Bupropion	◆	◆	◆	◆	◆
Citalopram	◆	■	◆	◆	■
Clomipramine	◆	■	◆	◆	■
Desipramine	◆	■	◆	◆	■
Desvenlafaxine	◆	◆	◆	◆	◆
Dosulepin	◆	■	◆	◆	■
Doxepin	◆	▲	◆	◆	▲
Duloxetine	◆	◆	◆	◆	◆
Escitalopram	◆	■	◆	◆	■
Fluoxetine	◆	■	◆	◆	■
Fluvoxamine	◆	▲	◆	●	▲
Imipramine	◆	■	◆	◆	■
Lithium	◆	■	◆	◆	■
Maprotiline	◆	■	◆	◆	■
Mianserin	◆	■	◆	◆	■
Milnacipran	◆	■	◆	◆	■
Mirtazapine	◆	■	◆	◆	■
Moclobemide	◆	●	◆	◆	●
Nefazodone	◆	■	◆	●	◆
Nortriptyline	◆	■	◆	◆	■
Paroxetine	◆	▲	◆	◆	▲
Phenelzine	●	●	●	●	●
Reboxetine	◆	◆	◆	◆	◆
Sertraline	◆	■	◆	◆	■
Tianeptine	◆	◆	◆	◆	◆
Trazodone	◆	■	◆	◆	■
Trimipramine	◆	■	◆	◆	■
Venlafaxine	◆	●	◆	◆	●
Vortioxetine	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HCC Therapies

**Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.**

Atezo + Bez, Atezolizumab + bevacizumab; LEN, lenvatinib; PEM, pembrolizumab; REG, regorafenib; SOR, sorafenib.

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Antidiabetics</b>					
Acarbose	◆	◆	◆	◆	◆
Albiglutide	◆	◆	◆	◆	▲
Alogliptin	◆	◆	◆	◆	▲
Canagliflozin	◆	◆	◆	■	■
Dapagliflozin	◆	◆	◆	■	■
Dulaglutide	◆	◆	◆	◆	▲
Empagliflozin	◆	◆	◆	■	■
Exenatide	◆	◆	◆	◆	▲
Glibenclamide (Glyburide)	◆	◆	◆	◆	▲
Gliclazide	◆	◆	◆	◆	▲
Glimepiride	◆	◆	◆	◆	▲
Glipizide	◆	◆	◆	◆	▲
Insulin	◆	◆	◆	◆	◆
Linagliptin	◆	◆	◆	▲	◆
Liraglutide	◆	◆	◆	◆	▲
Lixisenatide	◆	◆	◆	◆	▲
Metformin	◆	◆	◆	◆	▲
Nateglinide	◆	◆	◆	◆	▲
Pioglitazone	◆	◆	◆	◆	▲
Repaglinide	◆	◆	◆	◆	▲
Rosiglitazone	◆	◆	◆	◆	▲
Saxagliptin	◆	◆	◆	◆	▲
Semaglutide	◆	◆	◆	◆	▲
Sitagliptin	◆	◆	◆	◆	▲
Tirzepatide	◆	◆	◆	◆	▲
Tolbutamide	◆	◆	◆	◆	▲
Vildagliptin	◆	◆	◆	◆	▲
<b>Antifungals</b>					
Amphotericin B	◆	▲	▲	▲	■
Anidulafungin	◆	◆	◆	◆	◆
Caspofungin	◆	◆	◆	◆	◆
Clotrimazole (pessary)	◆	◆	◆	◆	◆
Clotrimazole (topical)	◆	◆	◆	◆	◆
Fluconazole	◆	■	◆	●	◆
Flucytosine	◆	▲	▲	▲	▲
Griseofulvin	◆	◆	◆	◆	◆
Isavuconazole	◆	◆	◆	●	◆
Itraconazole	◆	■	◆	■	■
Ketoconazole	◆	■	◆	●	■
Miconazole	◆	◆	◆	◆	◆
Nystatin	◆	◆	◆	◆	◆
Posaconazole	◆	■	◆	●	■
Terbinafine	◆	◆	◆	◆	◆
Voriconazole	◆	■	◆	●	■
<b>Antithrombotics</b>					
Avatrombopag	▲	◆	◆	◆	◆
Eltrombopag	▲	◆	◆	■	▲
Tranexamic acid	◆	◆	◆	◆	◆
<b>Antihistamines</b>					
Astemizole	◆	■	◆	◆	■
Bilastine	◆	◆	◆	◆	◆
Cetirizine	◆	◆	◆	◆	◆
Chlorphenamine	◆	◆	◆	◆	◆
Desloratadine	◆	◆	◆	◆	◆
Diphenhydramine	◆	▲	◆	◆	▲
Doxylamine	◆	◆	◆	◆	◆
Ebastine	◆	◆	◆	◆	◆
Fexofenadine	◆	◆	◆	◆	▲
Hydroxyzine	◆	●	◆	◆	●
Levocetirizine	◆	◆	◆	◆	◆
Loratadine	◆	◆	◆	◆	◆
Promethazine	◆	■	◆	◆	■
Terfenadine	◆	●	◆	◆	●

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Antimigraine Agents</b>					
Almotriptan	◆	◆	◆	◆	◆
Dihydroergotamine	◆	◆	◆	◆	◆
Eletriptan	◆	◆	◆	◆	◆
Eptinezumab	◆	◆	◆	◆	◆
Erenumab	◆	◆	◆	◆	◆
Ergotamine	◆	◆	◆	◆	◆
Fremanezumab	◆	◆	◆	◆	◆
Frovatriptan	◆	◆	◆	◆	◆
Galcanezumab	◆	◆	◆	◆	◆
Methylergonovine	◆	◆	◆	◆	◆
Naratriptan	◆	◆	◆	◆	◆
Pizotifen	◆	◆	◆	◆	◆
Rizatriptan	◆	◆	◆	◆	◆
Sumatriptan	◆	◆	◆	◆	◆
Zolmitriptan	◆	◆	◆	◆	◆
<b>Antiprotozoals</b>					
Amodiaquine	◆	◆	◆	◆	◆
Artemether	◆	●	◆	◆	●
Artemisinin	◆	●	◆	◆	●
Artesunate	◆	●	◆	◆	●
Atovaquone	◆	◆	■	◆	◆
Chloroquine	◆	■	◆	◆	■
Dihydroartemisinin	◆	◆	◆	◆	●
Doxycycline	◆	◆	◆	◆	◆
Halofantrine	◆	■	◆	◆	■
Hydroxychloroquine	◆	■	◆	◆	■
Lumefantrine	◆	●	◆	◆	●
Mefloquine	◆	■	◆	◆	■
Nitazoxanide	◆	◆	◆	◆	◆
Pentamidine	◆	■	◆	◆	■
Primaquine	◆	■	◆	◆	■
Proguanil	◆	◆	◆	◆	◆
Pyrimethamine	◆	◆	◆	◆	◆
Quinine	◆	■	◆	◆	■
Sodium stibogluconate	◆	■	◆	◆	■
Sulfadoxine	◆	◆	◆	◆	◆
<b>Antipsychotics/neuroleptics</b>					
Amisulpride	◆	■	◆	◆	■
Aripiprazole	◆	■	◆	◆	■
Asenapine	◆	■	◆	◆	■
Brexipiprazole	▲	▲	▲	▲	▲
Cariprazine	◆	▲	▲	▲	▲
Chlorpromazine	◆	■	◆	◆	■
Chlorprothixene	◆	◆	◆	◆	■
Clozapine	◆	■	▲	▲	■
Flupentixol	◆	●	◆	◆	●
Fluphenazine	◆	●	◆	◆	●
Haloperidol	◆	●	◆	◆	●
Iloperidone	◆	●	◆	◆	●
Levomepromazine	◆	■	◆	◆	■
Lurasidone	◆	■	◆	▲	■
Olanzapine	◆	■	◆	◆	■
Paliperidone	◆	■	◆	◆	■
Perazine	◆	▲	◆	◆	▲
Periciazine	◆	■	◆	◆	■
Perphenazine	◆	◆	◆	◆	◆
Pimozide	◆	●	◆	◆	●
Pipotiazine	◆	■	◆	◆	■
Prochlorperazine	◆	■	◆	◆	■
Promazine	◆	■	▲	▲	■
Quetiapine	◆	◆	◆	◆	◆
Risperidone	◆	■	◆	◆	■
Sulpiride	◆	■	◆	◆	■
Tiapride	◆	■	◆	◆	■
Trifluoperazine	◆	▲	◆	◆	▲
Ziprasidone	◆	●	◆	◆	●
Zuclopentixol	◆	●	◆	◆	●

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

*We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.*

# Interactions with HCC Therapies

**Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.**

Atezo + Bez, Atezolizumab + bevacizumab; LEN, lenvatinib; PEM, pembrolizumab; REG, regorafenib; SOR, sorafenib.

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Antivirals</b>					
Aciclovir	◆	◆	◆	◆	◆
Amantadine	◆	▲	◆	◆	▲
Ansuvimab	◆	◆	◆	◆	◆
Brincidofovir	◆	▲	▲	◆	◆
Brivudine	▲	◆	◆	◆	◆
Cidofovir	◆	▲	▲	◆	◆
Favipiravir	◆	◆	◆	◆	◆
Foscarnet	◆	■	◆	◆	■
Molnupiravir	◆	◆	◆	●	■
Nirmatrelvir/ritonavir	◆	◆	◆	●	■
Oseltamivir	◆	◆	◆	◆	◆
Palivizumab	◆	◆	◆	◆	◆
Remdesivir	◆	▲	◆	◆	▲
Rimantadine	◆	◆	◆	◆	◆
Sotrovimab	◆	◆	◆	◆	◆
Tecovirimat	◆	◆	◆	▲	▲
Tixagevimab/cilgavimab	◆	◆	◆	◆	◆
Valaciclovir	◆	◆	◆	◆	◆
Zanamivir	◆	◆	◆	◆	◆
<b>Anxiolytics/Hypnotics/Sedatives</b>					
Alprazolam	◆	◆	◆	◆	◆
Amobarbital	◆	◆	◆	●	●
Bromazepam	◆	◆	◆	◆	◆
Bromperidol	◆	■	◆	◆	●
Buspirone	◆	◆	◆	◆	◆
Clobazam	◆	◆	◆	◆	◆
Clorazepate	◆	◆	◆	◆	◆
Clotiapine	◆	■	◆	◆	■
Diazepam	◆	◆	◆	◆	◆
Estazolam	◆	◆	◆	◆	◆
Flurazepam	◆	◆	◆	◆	◆
Lorazepam	◆	◆	◆	◆	◆
Lormetazepam	◆	◆	◆	◆	◆
Midazolam (oral)	◆	◆	◆	◆	◆
Midazolam (parenteral)	◆	◆	◆	◆	◆
Oxazepam	◆	◆	◆	◆	◆
Quazepam	◆	◆	◆	◆	◆
Temazepam	◆	◆	◆	◆	◆
Triazolam	◆	◆	◆	◆	◆
Zaleplon	◆	◆	◆	◆	◆
Zolpidem	◆	◆	◆	◆	◆
Zopiclone	◆	◆	◆	◆	◆
<b>Beta Blockers</b>					
Atenolol	◆	▲	◆	▲	◆
Bisoprolol	◆	▲	◆	▲	▲
Carvedilol	◆	▲	◆	■	▲
Celiprolol	◆	▲	◆	▲	◆
Labetalol	◆	▲	◆	▲	▲
Metoprolol	◆	▲	◆	▲	◆
Nebivolol	◆	▲	◆	▲	◆
Oxprenolol	◆	▲	◆	■	◆
Pindolol	◆	▲	◆	▲	◆
Propranolol	◆	▲	◆	▲	▲
Sotalol	◆	■	◆	▲	■
Timolol	◆	▲	◆	▲	◆
<b>Bisphosphonates</b>					
Alendronic acid	▲	▲	◆	◆	▲
Clodronate	▲	▲	◆	◆	▲
Ibandronic acid	▲	▲	◆	◆	▲
Pamidronate	■	■	◆	◆	▲
Risedronate	▲	▲	◆	◆	▲
Zoledronic acid	■	■	◆	◆	▲

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Bronchodilators</b>					
Acidinium bromide	◆	◆	◆	◆	◆
Formoterol	◆	◆	◆	◆	◆
Indacaterol	◆	◆	◆	◆	◆
Ipratropium bromide	◆	◆	◆	◆	◆
Montelukast	◆	◆	◆	◆	◆
Omalizumab	◆	◆	◆	◆	◆
Reslizumab	◆	◆	◆	◆	◆
Salbutamol	◆	◆	◆	◆	◆
Salmeterol	◆	◆	◆	◆	◆
Theophylline	◆	◆	◆	◆	◆
Tiotropium	◆	◆	◆	◆	◆
Vilanterol	◆	◆	◆	◆	◆
Umeclidinium bromide	◆	◆	◆	◆	◆
<b>Calcium Channel Blockers</b>					
Amlodipine	◆	▲	◆	▲	◆
Diltiazem	◆	▲	◆	▲	◆
Felodipine	◆	▲	◆	▲	▲
Nicardipine	◆	▲	◆	▲	▲
Nifedipine	◆	▲	◆	▲	◆
Nisoldipine	◆	▲	◆	▲	◆
Nitrendipine	◆	▲	◆	▲	◆
Verapamil	◆	▲	◆	▲	◆

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

*We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.*

# Interactions with HCC Therapies

Charts revised March 2025. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

**Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.**

Atezo + Bez, Atezolizumab + bevacizumab; LEN, lenvatinib; PEM, pembrolizumab; REG, regorafenib; SOR, sorafenib.

Cancer Therapies	Atezo + Bez	LEN	PEM	REG	SOR
Abiraterone	▲	■	◆	◆	■
Acalabrutinib	◆	◆	▲	▲	▲
Afatinib	◆	◆	◆	■	■
Alectinib	▲	◆	▲	▲	▲
Alpelisib	▲	▲	◆	■	▲
Amivantamab	◆	◆	◆	◆	◆
Anastrozole	◆	◆	◆	◆	◆
Apalutamide	▲	■	◆	●	●
Asciminib	▲	■	▲	■	■
Asparaginase	◆	◆	◆	◆	◆
Atezolizumab	●	▲	▲	▲	▲
Avapritinib	▲	■	▲	▲	▲
Avelumab	◆	◆	◆	◆	◆
Axitinib	◆	◆	■	◆	◆
Azacitidine	▲	▲	▲	▲	▲
Belantamab mafodotin	▲	▲	▲	▲	▲
Bendamustine	▲	■	▲	▲	■
Bevacizumab	●	◆	■	■	◆
Bexarotene	◆	◆	◆	■	◆
Bicalutamide	◆	■	◆	▲	■
Blinatumomab	◆	◆	■	▲	◆
Bortezomib	▲	■	■	◆	■
Bosutinib	▲	■	■	▲	■
Brentuximab vedotin	◆	◆	■	◆	◆
Capecitabine	▲	■	■	◆	■
Carboplatin	▲	◆	▲	▲	■
Carfilzomib	◆	■	▲	▲	■
Cetuximab	▲	◆	◆	◆	◆
Chlorambucil	▲	◆	■	▲	◆
Cisplatin	▲	◆	■	▲	■
Cyclophosphamide	◆	◆	▲	▲	◆
Daratumumab	◆	◆	■	▲	■
Dasatinib	▲	■	■	◆	■
Dinutuximab beta	▲	▲	▲	▲	◆
Dostarlimab	▲	◆	▲	▲	◆
Doxorubicin	◆	▲	■	▲	■
Durvalumab	◆	▲	◆	◆	◆
Elotuzumab	◆	▲	◆	◆	◆
Elranatamab	▲	▲	▲	▲	◆
Enzalutamide	◆	■	◆	●	●
Eporitamab	▲	▲	▲	▲	◆
Epirubicin	▲	■	▲	▲	■
Erlotinib	◆	◆	◆	◆	◆
Estramustine	▲	◆	◆	◆	◆
Etoposide	▲	◆	■	■	◆
Everolimus	◆	▲	●	▲	■
Exemestane	▲	◆	◆	◆	◆
Fludarabine	◆	■	■	◆	◆
Fluorouracil (5-FU)	▲	■	▲	▲	▲
Gefitinib	▲	◆	■	■	◆
Gemcitabine	▲	◆	■	▲	■
Gemtuzumab ozogamicin	▲	▲	▲	▲	◆
Glofitamab	▲	▲	▲	▲	◆
Hydroxyurea (Hydroxycarbamide)	▲	▲	▲	▲	▲
Ibrutinib	▲	▲	▲	▲	◆
Idarubicin	▲	◆	■	▲	◆
Idelalisib	▲	◆	■	●	◆
Imatinib	▲	■	■	■	■
Inotuzumab ozogamicin	▲	■	▲	▲	■
Ipilimumab	▲	◆	■	▲	■
Irinotecan	▲	◆	■	■	■
Isatuximab	◆	▲	■	◆	◆
Ixazomib	◆	◆	■	▲	◆
Lapatinib	◆	■	◆	◆	■

Cancer Therapies continued	Atezo + Bez	LEN	PEM	REG	SOR
Letrozole	▲	◆	◆	◆	◆
Loncastuximab tesirine	▲	▲	▲	▲	▲
Medroxyprogesterone (oncology)	◆	◆	◆	◆	◆
Mercaptopurine	◆	◆	■	▲	◆
Mesna	▲	◆	◆	◆	◆
Methotrexate	▲	◆	■	■	■
Mitoxantrone	▲	◆	■	■	■
Mogamulizumab	◆	◆	◆	◆	◆
Nilotinib	▲	■	◆	■	■
Niraparib	▲	■	■	▲	◆
Nivolumab	◆	◆	■	◆	◆
Obinutuzumab	▲	◆	◆	◆	◆
Ofatumumab	▲	◆	■	▲	◆
Olaparib	▲	▲	■	▲	▲
Olaratumab	▲	◆	■	◆	◆
Osimertinib	▲	■	▲	▲	■
Oxaliplatin	▲	■	■	▲	■
Paclitaxel	▲	▲	■	▲	■
Panitumumab	▲	◆	◆	◆	◆
Panobinostat	▲	●	■	▲	●
Pomalidomide	■	■	■	■	▲
Ponatinib	■	■	■	■	▲
Pertuzumab	◆	▲	▲	▲	◆
Ramucirumab	▲	▲	◆	▲	◆
Retifanlimab	▲	▲	■	▲	▲
Rituximab	▲	◆	■	▲	◆
Ruxolitinib	▲	▲	▲	▲	▲
Sacituzumab govitecan	▲	▲	▲	●	●
Sunitinib	■	■	■	▲	■
Talazoparib	▲	▲	▲	■	▲
Tamoxifen	◆	▲	◆	◆	▲
Tegafur/Gimeracil/Oteracil	▲	▲	◆	▲	▲
Temsirolimus	▲	◆	●	◆	◆
Tepotinib	◆	■	◆	◆	■
Tisotumab vedotin	▲	▲	▲	▲	▲
Tivozanib	■	■	▲	▲	■
Topotecan (IV)	▲	▲	▲	▲	▲
Topotecan (oral)	▲	▲	▲	■	■
Trametinib	◆	◆	◆	◆	◆
Trastuzumab	▲	▲	▲	▲	◆
Trastuzumab deruxtecan	▲	▲	▲	▲	◆
Trastuzumab emtansine	▲	▲	▲	▲	◆
Trifluridine/tipiracil	▲	▲	▲	▲	▲
Vinblastine	▲	◆	■	▲	◆
Vincristine	▲	◆	■	▲	◆
Vinorelbine	◆	◆	■	◆	▲

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HCC Therapies

**Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.**

Atezo + Bez, Atezolizumab + bevacizumab; LEN, lenvatinib; PEM, pembrolizumab; REG, regorafenib; SOR, sorafenib.

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Contraceptives</b>					
Conjugated estrogens (HRT)	◆	◆	◆	◆	◆
Desogestrel (POP)	◆	■	◆	◆	◆
Desogestrel/ethinyl-estradiol (COC) (>20 µg)	◆	■	◆	◆	◆
Desogestrel/ethinyl-estradiol (COC) (≤20 µg)	◆	■	◆	◆	◆
Dienogest	◆	■	◆	◆	◆
Drospirenone (POP)	◆	■	◆	◆	◆
Drospirenone/estradiol (HRT)	◆	◆	◆	◆	◆
Drospirenone/ethinyl-estradiol (COC) (>20 µg)	◆	■	◆	◆	◆
Drospirenone/ethinyl-estradiol (COC) (≤20 µg)	◆	■	◆	◆	◆
Dydrogesterone/estradiol (HRT)	◆	◆	◆	◆	◆
Ethinylestradiol (>20 µg)	◆	■	◆	◆	◆
Ethinylestradiol (≤20 µg)	◆	■	◆	◆	◆
Etonogestrel (implant)	◆	■	◆	◆	◆
Etonogestrel (vaginal ring)	◆	■	◆	◆	◆
Gestodene/ethinylestradiol (COC) (>20 µg)	◆	■	◆	◆	◆
Gestodene/ethinylestradiol (COC) (≤20 µg)	◆	■	◆	◆	◆
Levonorgestrel (Emergency Contraception)	◆	■	◆	◆	◆
Levonorgestrel (HRT)	◆	◆	◆	◆	◆
Levonorgestrel (implant)	◆	■	◆	◆	◆
Levonorgestrel (IUD)	◆	■	◆	◆	◆
Levonorgestrel (POP)	◆	■	◆	◆	◆
Levonorgestrel/ethinyl-estradiol (COC) (>20 µg)	◆	■	◆	◆	◆
Levonorgestrel/ethinyl-estradiol (COC) (>20 µg)	◆	■	◆	◆	◆
Medroxyprogesterone (depot)	◆	■	◆	◆	◆
Medroxyprogesterone (oral)	◆	■	◆	◆	◆
Medroxyprogesterone/conjugated estrogens (HRT)	◆	◆	◆	◆	◆
Medroxyprogesterone/estradiol (HRT)	◆	◆	◆	◆	◆
Micronized progesterone (HRT)	◆	◆	◆	◆	◆
Norelgestromin/ethinylestradiol (patch)	◆	■	◆	◆	◆
Norethisterone (Norethindrone) (depot injection)	◆	■	◆	◆	◆
Norethisterone (Norethindrone) (POP)	◆	■	◆	◆	◆
Norethisterone (Norethindrone)/estradiol (HRT)	◆	◆	◆	◆	◆
Norethisterone (Norethindrone)/ethinylestradiol (COC)	◆	■	◆	◆	◆
Norethisterone (Norethindrone)/mestranol (COC)	◆	■	◆	◆	◆
Norgestimate/ethinylestradiol (COC)	◆	■	◆	◆	◆
Norgestrel/conjugated estrogens (HRT)	◆	◆	◆	◆	◆
Norgestrel/ethinylestradiol (COC)	◆	■	◆	◆	◆
Testosterone	◆	◆	◆	◆	◆
<b>Erectile Dysfunction Agents</b>					
Sildenafil	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	◆
Vardenafil	◆	◆	◆	◆	◆
Yohimbine	◆	◆	◆	◆	◆

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Gastrointestinal Agents</b>					
Aluminium hydroxide	◆	◆	◆	◆	◆
Alverine citrate	◆	◆	◆	◆	◆
Antacids	◆	◆	◆	◆	◆
Aprepitant	◆	◆	◆	■	◆
Bisacodyl	◆	◆	◆	◆	◆
Bismuth subsalicylate	◆	◆	◆	◆	◆
Cimetidine	◆	◆	◆	▲	◆
Cisapride	◆	■	◆	◆	■
Cyclizine	◆	◆	◆	◆	◆
Dantron	◆	◆	◆	◆	◆
Docusate sodium	◆	◆	◆	◆	◆
Domperidone	◆	●	◆	◆	●
Droperidol	◆	●	◆	◆	●
Esomeprazole	◆	◆	◆	◆	◆
Famotidine	◆	▲	◆	◆	▲
Granisetron	◆	■	◆	◆	■
Hyoscine (Scopolamine)	◆	◆	◆	◆	◆
Hyoscine butylbromide	◆	◆	◆	◆	◆
Hyoscine hydrobromide (Scopolamine hydrobromide)	◆	◆	◆	◆	◆
Ispaghula husk	◆	◆	◆	◆	◆
Lactulose	◆	◆	◆	◆	◆
Lafutidine	◆	◆	◆	▲	◆
Lansoprazole	◆	◆	◆	◆	◆
Linacotide	◆	◆	◆	◆	◆
Loperamide	◆	◆	◆	◆	◆
Lubiprostone	◆	◆	◆	◆	◆
Macrogol	◆	▲	◆	▲	▲
Mebeverine	◆	◆	◆	◆	◆
Mesalazine	◆	◆	◆	◆	◆
Methylcellulose	◆	◆	◆	◆	◆
Metoclopramide	◆	■	◆	◆	■
Naloxegol	◆	◆	◆	◆	◆
Nizatidine	◆	◆	◆	◆	◆
Omeprazole	◆	◆	◆	◆	◆
Ondansetron	◆	■	◆	◆	■
Pantoprazole	◆	◆	◆	◆	◆
Prucalopride	◆	◆	◆	◆	◆
Rabeprazole	◆	◆	◆	◆	◆
Ranitidine	◆	◆	◆	◆	◆
Roxatidine	◆	◆	◆	◆	◆
Senna	◆	◆	◆	◆	◆
Simeticone	◆	◆	◆	◆	◆
Sulfasalazine	◆	◆	◆	●	▲
Trimebutine	◆	◆	◆	◆	◆
Vonoprazan	◆	■	◆	▲	■
<b>HCC Therapies</b>					
Atezolizumab + bevacizumab		▲	▲	▲	▲
Lenvatinib	▲		▲	▲	▲
Pembrolizumab	▲	▲		▲	▲
Regorafenib	▲	▲	▲		■
Sorafenib	▲	▲	▲		
<b>Hepatitis B Drugs</b>					
Adefovir	◆	◆	◆	◆	◆
Entecavir	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆
Peginterferon alfa-2a	■	▲	▲	▲	▲
Peginterferon alfa-2b	■	▲	▲	▲	▲
Ribavirin	◆	▲	■	▲	▲
Telbivudine	◆	◆	◆	◆	◆
Tenofovir alafenamide (TAF)	◆	◆	◆	◆	▲
Tenofovir-DF	◆	◆	◆	◆	▲
<b>Hepatitis C Drugs</b>					
Daclatasvir	◆	◆	◆	◆	◆
Elbasvir/Grazoprevir	◆	◆	◆	▲	■
Glecaprevir/Pibrentasvir	◆	◆	◆	▲	◆
Ledipasvir/Sofosbuvir	◆	◆	◆	■	◆
OBV/PTV/r	◆	◆	◆	●	■
OBV/PTV/r + Dasabuvir	◆	◆	◆	●	■
Ravidasvir	◆	◆	◆	■	◆
Ribavirin	◆	▲	■	▲	▲
Sofosbuvir (SOF)	◆	◆	◆	◆	◆
SOF/Velpatasvir	◆	◆	◆	■	◆
SOF/Velpatasvir/Voxilaprevir	◆	◆	◆	■	◆
<b>Hepatitis D Entry Inhibitor</b>					
Bulevirtide	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HCC Therapies

Charts revised March 2025. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

**Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.**

Atezo + Bez, Atezolizumab + bevacizumab; LEN, lenvatinib; PEM, pembrolizumab; REG, regorafenib; SOR, sorafenib.

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Herbals/Supplements/Vitamins</b>					
Aloe vera	◆	◆	◆	◆	◆
Ascorbic acid (Vitamin C)	◆	◆	◆	◆	◆
Ashwagandha (Withania somnifera)	◆	◆	◆	◆	◆
Black cohosh (A. racemosa)	◆	◆	◆	◆	◆
Cat's claw (U. tomentosa)	◆	◆	◆	◆	◆
Colecalciferol (Vitamin D3)	◆	◆	◆	◆	◆
Cyanocobalamin (B12)	◆	◆	◆	◆	◆
Diosmin	◆	◆	◆	◆	◆
Echinacea	◆	◆	◆	◆	◆
Enteric feeds	◆	◆	◆	◆	◆
Eucalyptus globulus	◆	◆	◆	◆	◆
Ferrous sulfate	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆
Garlic	◆	◆	◆	◆	◆
Ginger (Z. officinale)	◆	◆	◆	◆	◆
Ginkgo biloba	◆	◆	◆	◆	◆
Ginseng	◆	◆	◆	◆	◆
Goldenseal (H. canadensis)	◆	◆	◆	◆	◆
Grape seed extract	◆	◆	◆	◆	◆
Grapefruit juice	◆	◆	◆	◆	◆
Green tea (C. sinensis)	◆	◆	◆	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆
Inula racemosa	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆
Kava kava (P. methysticum)	◆	◆	◆	◆	◆
L-lysine	◆	◆	◆	◆	◆
Menthol	◆	◆	◆	◆	◆
Milk thistle	◆	◆	◆	◆	◆
Mucuna pruriens	◆	◆	◆	◆	◆
Niacin (Vitamin B3)	◆	◆	◆	◆	◆
Oral nutritional supplements	◆	◆	◆	◆	◆
Oregano oil	◆	◆	◆	◆	◆
Pyridoxine (Vitamin B6)	◆	◆	◆	◆	◆
Retinol (Vitamin A)	◆	◆	◆	◆	◆
Riboflavin (Vitamin B2)	◆	◆	◆	◆	◆
Saw palmetto (S. repens)	◆	◆	◆	◆	◆
St John's wort	◆	◆	◆	◆	◆
THC capsules	◆	◆	◆	◆	◆
Thiamine (Vitamin B1)	◆	◆	◆	◆	◆
Turmeric (curcumin)	◆	◆	◆	◆	◆
Valerian	◆	◆	◆	◆	◆
Vitamin E	◆	◆	◆	◆	◆
Zinc	◆	◆	◆	◆	◆
<b>HIV Drugs</b>					
<b>Entry/Integrase Inhibitors</b>					
Albuvirtide	◆	◆	◆	◆	◆
Bictegravir/FTC/TAF	◆	◆	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆	◆	◆
Cabotegravir/rilpivirine (LA)	◆	◆	◆	◆	◆
Dolutegravir	◆	◆	◆	◆	◆
Dolutegravir/3TC	◆	◆	◆	◆	◆
Dolutegravir/ABC/3TC	◆	◆	◆	◆	◆
Dolutegravir/rilpivirine	◆	◆	◆	◆	◆
Elvitegravir/cobi /FTC/TAF	◆	◆	◆	◆	◆
Elvitegravir/cobi/FTC/TDF	◆	◆	◆	◆	◆
Enfuvirtide	◆	◆	◆	◆	◆
Fostemsavir	◆	◆	◆	◆	◆
Ibalizumab-uiyk	◆	◆	◆	◆	◆
Lenacapavir	◆	◆	◆	◆	◆
Maraviroc	◆	◆	◆	◆	◆
Raltegravir	◆	◆	◆	◆	◆
<b>NNRTIs</b>					
Dapivirine	◆	◆	◆	◆	◆
Doravirine	◆	◆	◆	◆	◆
Doravirine/3TC/TDF	◆	◆	◆	◆	◆
Efavirenz	◆	◆	◆	◆	◆
Etravirine	◆	◆	◆	◆	◆
Nevirapine	◆	◆	◆	◆	◆
Rilpivirine	◆	◆	◆	◆	◆
Rilpivirine/FTC/TAF	◆	◆	◆	◆	◆
<b>NRTIs</b>					
Abacavir	◆	◆	◆	◆	◆
Didanosine	◆	◆	◆	◆	◆
Emtricitabine (FTC)	◆	◆	◆	◆	◆
Emtricitabine + TAF	◆	◆	◆	◆	◆
Emtricitabine + TDF	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆
Stavudine	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	◆	◆
Zidovudine	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	Atezo + Bez	LEN	PEM	REG	SOR
<b>HIV Drugs continued</b>					
<b>Protease Inhibitors</b>					
Atazanavir alone	◆	◆	◆	◆	◆
Atazanavir/cobicistat	◆	◆	◆	◆	◆
Atazanavir + ritonavir	◆	◆	◆	◆	◆
Darunavir/cobicistat	◆	◆	◆	◆	◆
Darunavir/cobi/FTC/TAF	◆	◆	◆	◆	◆
Darunavir + ritonavir	◆	◆	◆	◆	◆
Fosamprenavir	◆	◆	◆	◆	◆
Indinavir	◆	◆	◆	◆	◆
Lopinavir	◆	◆	◆	◆	◆
Ritonavir	◆	◆	◆	◆	◆
Tipranavir	◆	◆	◆	◆	◆
<b>Hypertension/Heart Failure Agents</b>					
Acebutolol	◆	◆	◆	◆	◆
Aliskiren	◆	◆	◆	◆	◆
Ambrisentan	◆	◆	◆	◆	◆
Amiloride	◆	◆	◆	◆	◆
Azilsartan	◆	◆	◆	◆	◆
Benazepril	◆	◆	◆	◆	◆
Bendroflumethiazide	◆	◆	◆	◆	◆
Bosentan	◆	◆	◆	◆	◆
Bumetanide	◆	◆	◆	◆	◆
Candesartan	◆	◆	◆	◆	◆
Captopril	◆	◆	◆	◆	◆
Chlorthalidone	◆	◆	◆	◆	◆
Chlortalidone	◆	◆	◆	◆	◆
Cilazapril	◆	◆	◆	◆	◆
Clevidipine	◆	◆	◆	◆	◆
Clonidine	◆	◆	◆	◆	◆
Doxazosin	◆	◆	◆	◆	◆
Enalapril	◆	◆	◆	◆	◆
Eplerenone	◆	◆	◆	◆	◆
Epoprostenol	◆	◆	◆	◆	◆
Eprosartan	◆	◆	◆	◆	◆
Fosinopril	◆	◆	◆	◆	◆
Furosemide	◆	◆	◆	◆	◆
Hydralazine	◆	◆	◆	◆	◆
Hydrochlorothiazide	◆	◆	◆	◆	◆
Iloprost	◆	◆	◆	◆	◆
Indapamide	◆	◆	◆	◆	◆
Irbesartan	◆	◆	◆	◆	◆
Isradipine	◆	◆	◆	◆	◆
Ivabradine	◆	◆	◆	◆	◆
Lacidipine	◆	◆	◆	◆	◆
Lercanidipine	◆	◆	◆	◆	◆
Lisinopril	◆	◆	◆	◆	◆
Losartan	◆	◆	◆	◆	◆
Macitentan	◆	◆	◆	◆	◆
Methyldopa	◆	◆	◆	◆	◆
Metolazone	◆	◆	◆	◆	◆
Moxonidine	◆	◆	◆	◆	◆
Olmesartan	◆	◆	◆	◆	◆
Perindopril	◆	◆	◆	◆	◆
Prazosin	◆	◆	◆	◆	◆
Quinapril	◆	◆	◆	◆	◆
Ramipril	◆	◆	◆	◆	◆
Ranolazine	◆	◆	◆	◆	◆
Rilmenidine	◆	◆	◆	◆	◆
Riociguat	◆	◆	◆	◆	◆
Sacubitril/valsartan	◆	◆	◆	◆	◆
Selexipag	◆	◆	◆	◆	◆
Sildenafil	◆	◆	◆	◆	◆
Sodium nitroprusside	◆	◆	◆	◆	◆
Spirolactone	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	◆
Telmisartan	◆	◆	◆	◆	◆
Torsemide	◆	◆	◆	◆	◆
Trandolapril	◆	◆	◆	◆	◆
Treprostinil	◆	◆	◆	◆	◆
Valsartan	◆	◆	◆	◆	◆
Xipamide	◆	◆	◆	◆	◆
Zofenopril	◆	◆	◆	◆	◆

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HCC Therapies

Charts revised March 2025. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

**Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.**

Atezo + Bez, Atezolizumab + bevacizumab; LEN, lenvatinib; PEM, pembrolizumab; REG, regorafenib; SOR, sorafenib.

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Illicit/Recreational</b>					
Alcohol	◆	◆	◆	◆	◆
Amphetamine	◆	◆	◆	◆	◆
Bromazolam	◆	◆	◆	◆	◆
Cannabis	◆	◆	◆	◆	◆
Carfentanil	◆	◆	◆	◆	◆
Cocaine	◆	●	◆	◆	●
Ecstasy (MDMA)	◆	●	◆	◆	●
Etizolam	◆	◆	◆	◆	◆
Fentanyl (Recreational)	◆	◆	◆	◆	◆
GHB (Gamma-hydroxybutyrate)	◆	◆	◆	◆	◆
Heroin	◆	◆	◆	◆	◆
LSD (Lysergic acid diethylamide)	◆	◆	◆	◆	◆
Mephedrone	◆	◆	◆	◆	◆
Methamphetamine	◆	◆	◆	◆	◆
Nitazenes	◆	◆	◆	▲	●
Nicotine	◆	◆	◆	◆	◆
Phencyclidine (PCP)	◆	◆	◆	◆	◆
Xylazine	◆	■	◆	▲	■
<b>Immunosuppressants</b>					
Abatacept	▲	◆	▲	▲	◆
Adalimumab	▲	◆	▲	▲	◆
Alemtuzumab	▲	◆	●	◆	◆
Anakinra	▲	▲	▲	▲	▲
Azathioprine	▲	▲	●	▲	▲
Baricitinib	▲	▲	▲	▲	▲
Basiliximab	▲	◆	●	◆	◆
Belimumab	▲	◆	◆	◆	◆
Bimekizumab	▲	◆	◆	◆	◆
Brodalumab	▲	◆	●	◆	◆
Canakinumab	▲	▲	▲	▲	▲
Ciclosporin	▲	◆	●	●	▲
Cladribine (oral)	▲	▲	▲	■	▲
Eculizumab	▲	◆	●	◆	◆
Etanercept	▲	◆	●	◆	◆
Fingolimod	▲	◆	●	◆	◆
Golimumab	▲	▲	▲	▲	▲
Guselkumab	▲	◆	◆	◆	◆
Infliximab	▲	▲	▲	▲	▲
Ixekizumab	▲	◆	◆	◆	◆
Lenalidomide	▲	◆	●	◆	◆
Mirikizumab	▲	◆	◆	◆	◆
Mycophenolate	▲	▲	●	■	▲
Pirfenidone	▲	◆	●	◆	◆
Ravulizumab	▲	◆	◆	◆	◆
Risankizumab	▲	◆	◆	◆	◆
Sarilumab	▲	▲	▲	▲	▲
Secukinumab	▲	◆	◆	◆	◆
Siltuximab	▲	▲	▲	▲	▲
Sirolimus	▲	▲	●	▲	■
Tacrolimus	▲	■	●	●	■
Tildrakizumab	▲	◆	◆	◆	◆
Tocilizumab	▲	▲	▲	▲	▲
Tralokinumab	▲	◆	◆	◆	◆
Ublituximab	▲	◆	◆	◆	◆
Upadacitinib	▲	▲	▲	▲	▲
Ustekinumab	▲	◆	◆	◆	◆
Vedolizumab	▲	◆	◆	◆	◆
<b>Lipid Lowering Agents</b>					
Alirocumab	◆	◆	◆	◆	◆
Atorvastatin	◆	◆	◆	■	■
Bempedoic acid	◆	◆	◆	◆	◆
Bezafibrate	◆	◆	◆	◆	◆
Evolocumab	◆	◆	◆	◆	◆
Ezetimibe	◆	◆	◆	▲	▲
Fenofibrate	◆	◆	◆	◆	◆
Fish oils	◆	◆	◆	◆	◆
Fluvastatin	◆	◆	◆	■	◆
Gemfibrozil	◆	◆	◆	◆	◆
Icosapent ethyl	◆	◆	◆	◆	◆
Lovastatin	◆	◆	◆	◆	◆
Pitavastatin	◆	◆	◆	◆	▲
Pravastatin	◆	◆	◆	◆	▲
Rosuvastatin	◆	◆	◆	■	▲
Simvastatin	◆	◆	◆	■	▲

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Other Drugs</b>					
Acamprosate	◆	◆	◆	◆	◆
Acetazolamide	◆	◆	◆	◆	◆
Acitretin	◆	◆	◆	◆	◆
Activated charcoal	◆	▲	◆	▲	▲
Allopurinol	◆	◆	■	◆	◆
Atomoxetine	◆	■	◆	◆	■
Atropine	◆	◆	◆	◆	◆
Baclofen	◆	◆	◆	◆	◆
Bamlanivimab	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆
Betahistine	◆	◆	◆	◆	◆
Bimatoprost	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	◆
Brimonidine	◆	◆	◆	◆	◆
Brinzolamide	◆	◆	◆	◆	◆
Bromocriptine	◆	◆	◆	◆	◆
Burosumab	◆	◆	◆	◆	◆
Calcitonin	◆	◆	◆	◆	◆
Calcium carbimide	◆	◆	◆	◆	◆
Calcium resonium	◆	◆	◆	◆	◆
Cannabidiol (CBD)	◆	◆	◆	◆	◆
Carbimazole	◆	◆	◆	◆	◆
Carisoprodol	◆	◆	◆	◆	◆
Casirivimab/imdevimab	◆	◆	◆	◆	◆
Cilostazol	◆	■	◆	◆	■
Clomifene	◆	◆	◆	◆	◆
Colchicine	◆	◆	◆	◆	◆
Colestyramine	◆	▲	◆	■	▲
Conivaptan	◆	◆	◆	●	◆
Convalescent plasma (COVID-19)	◆	◆	◆	◆	◆
COVID-19 vaccines	◆	◆	◆	◆	◆
Crizanlizumab	◆	◆	◆	◆	◆
Cyclobenzaprime	◆	◆	◆	◆	◆
Cyproterone acetate	◆	●	●	●	●
Cytisine	◆	◆	◆	◆	◆
Darbepoetin	◆	◆	◆	◆	◆
Deferiprone	◆	◆	◆	◆	◆
Denosumab	◆	◆	◆	◆	◆
Dexamfetamine	◆	◆	◆	◆	◆
Dextromethorphan	◆	◆	◆	◆	◆
Disulfiram	◆	◆	◆	◆	◆
Donepezil	◆	■	◆	◆	■
Dorzolamide	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆
Eliglustat	◆	▲	◆	◆	▲
Emicizumab	◆	◆	◆	◆	◆
Epoetin alfa	◆	◆	◆	◆	◆
Etelcalcetide	◆	◆	◆	◆	◆
Faricimab	◆	◆	◆	◆	◆
Febuxostat	◆	◆	◆	◆	◆
Filgrastim	◆	◆	◆	◆	◆
Filbanserin	◆	◆	◆	◆	◆
Gadopentetate (gadolinium)	◆	◆	◆	◆	◆
Glucose monohydrate (IV)	◆	◆	◆	◆	◆
Glycerol phenylbutyrate	◆	◆	◆	◆	◆
Goserelin acetate	◆	■	◆	◆	■
Guanfacine	◆	●	◆	◆	●
Influenza vaccine	◆	◆	◆	◆	◆
Interferon beta	◆	▲	▲	▲	▲

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.  
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

# Interactions with HCC Therapies

Charts revised March 2025. Full information available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)

**Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.**

Atezo + Bez, Atezolizumab + bevacizumab; LEN, lenvatinib; PEM, pembrolizumab; REG, regorafenib; SOR, sorafenib.

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Other Drugs Continued</b>					
Isosorbide mononitrate	◆	▲	◆	▲	◆
Isotretinoin	◆	◆	◆	◆	◆
Lanadelumab	◆	◆	◆	◆	◆
Lanreotide	◆	◆	◆	◆	◆
Lebrikizumab	◆	◆	◆	◆	◆
Leuprorelin acetate	◆	■	◆	◆	■
Levothyroxine	◆	■	◆	◆	◆
Lisdexamfetamine	◆	▲	◆	◆	▲
Lofexidine	◆	■	◆	◆	■
Lumacaftor/Ivacaftor	◆	◆	◆	●	●
Magnesium	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆
Memantine	◆	▲	◆	◆	■
Mepolizumab	◆	◆	◆	◆	◆
Methimazole (Thiamazole)	▲	▲	▲	▲	▲
Methylphenidate	◆	◆	◆	◆	▲
Minoxidil	◆	◆	◆	▲	▲
Modafinil	◆	◆	◆	■	■
Nafidrofuryl	◆	◆	◆	◆	◆
Nalmefene	◆	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	▲	▲
Neostigmine	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆
Nusinersen	◆	■	◆	◆	■
Ocrelizumab	◆	◆	◆	◆	◆
Orlistat	◆	▲	◆	▲	▲
Penicillamine	◆	◆	◆	◆	◆
Pentoxifylline	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆
Piracetam	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆
Propylthiouracil	◆	▲	▲	▲	▲
Protamine sulphate	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆
Pyridostigmine	◆	◆	◆	◆	◆
Raloxifene	◆	◆	◆	▲	▲
Ranibizumab	◆	◆	◆	◆	◆
Romosozumab	◆	◆	◆	◆	▲
Rozanolizumab	■	◆	■	◆	◆
Sevelamer	◆	▲	◆	▲	▲
Sodium zirconium cyclosilicate	◆	◆	◆	◆	◆
Strontium ranelate	◆	◆	◆	◆	◆
Thalidomide	▲	■	■	▲	◆
Triptorelin	◆	■	◆	◆	■
Varenicline	◆	◆	◆	◆	◆

	Atezo + Bez	LEN	PEM	REG	SOR
<b>Oxytocics</b>					
Ergometrine (ergonovine)	◆	◆	◆	◆	◆
Mifepristone	◆	◆	◆	◆	◆
Misoprostol	◆	◆	◆	◆	◆
<b>Parkinsonism Agents</b>					
Benzotropine	◆	◆	◆	◆	◆
Carbidopa	◆	◆	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	◆
Pramipexole	◆	◆	◆	◆	◆
Procyclidine	◆	◆	◆	◆	◆
Rasagiline	◆	◆	◆	◆	◆
Ropinirole	◆	◆	◆	◆	◆
<b>PBC Agents</b>					
Obeticholic acid	◆	◆	◆	◆	◆
Ursodeoxycholic acid	◆	◆	◆	◆	◆
<b>Steroids</b>					
Beclometasone	▲	◆	●	◆	◆
Betamethasone	▲	◆	●	◆	◆
Budesonide	▲	◆	●	◆	◆
Ciclesonide	▲	◆	●	◆	◆
Clobetasol (topical)	◆	◆	◆	◆	◆
Clobetasone (topical)	◆	◆	◆	◆	◆
Dexamethasone >16 mg	▲	◆	■	●	■
Dexamethasone ≤16 mg	▲	◆	■	▲	◆
Fludrocortisone	▲	◆	●	◆	◆
Flunisolide	▲	◆	●	◆	◆
Fluticasone	▲	◆	●	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	◆
Methylprednisolone	▲	◆	●	◆	◆
Mometasone	▲	◆	●	◆	◆
Prednicarbate	◆	◆	●	◆	◆
Prednisone	▲	◆	●	◆	▲
Triamcinolone	▲	◆	●	◆	◆
<b>Urological Agents</b>					
Alfuzosin	◆	■	◆	◆	■
Desmopressin	◆	◆	◆	◆	◆
Dutasteride	◆	◆	◆	◆	◆
Finasteride	◆	◆	◆	◆	◆
Mirabegron	◆	▲	◆	◆	▲
Silodosin	◆	◆	◆	◆	■
Solifenacin	◆	■	◆	◆	■
Tamsulosin	◆	◆	◆	◆	◆
Tolterodine	◆	■	◆	◆	■
Trospium	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

**Key to symbols**

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

**Notes**

- Further information is available at [www.hep-druginteractions.org](http://www.hep-druginteractions.org)
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,  
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

*We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.*